C. Coppin (2008)
Immunotherapy for renal cell cancer in the era of targeted therapyExpert Review of Anticancer Therapy, 8
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovačević, V. Lesovoy, I. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R. Motzer (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.The New England journal of medicine, 356 22
Thomas Hutson, I. Davis, J. Machiels, P. Souza, K. Baker, W. Bordogna, R. Westlund, T. Crofts, L. Pandite, R. Figlin (2008)
Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitorJournal of Clinical Oncology, 26
D. Osoba, G. Rodrigues, J. Myles, B. Zee, J. Pater (1998)
Interpreting the significance of changes in health-related quality-of-life scores.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 1
(2010)
Go to jco.org/alerts to sign up. Sternberg et al 1068
A. Scarpelli, Saul Paiva, I. Pordeus, M. Ramos-Jorge, James Varni, Paul Allison, Maria Ramos, James W
Health and Quality of Life Outcomes Measurement Properties of the Brazilian Version of the Pediatric Quality of Life Inventory (pedsql™) Cancer Module Scale
B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena, S. Ou, L. Archer, J. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. Small (2008)
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
A. Kibel (2009)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialYearbook of Urology, 2009
D. Spronsen, K. Weijer, P. Mulders, P. Mulder (2005)
Novel treatment strategies in clear-cell metastatic renal cell carcinoma.Anti-cancer drugs, 16 7
R. Motzer, M. Michaelson, J. Rosenberg, R. Bukowski, B. Curti, D. George, G. Hudes, B. Redman, K. Margolin, G. Wilding (2007)
Sunitinib efficacy against advanced renal cell carcinoma.The Journal of urology, 178 5
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, Thomas Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R. Bukowski (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma.The New England journal of medicine, 356 2
H. Hurwitz, A. Dowlati, S. Savage, N. Fernando, S. Lasalvia, B. Whitehead, B. Suttle, D. Collins, P. Ho, L. Pandite (2005)
Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumorsJournal of Clinical Oncology, 23
R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy Kim, I. Chen, P. Bycott, C. Baum, R. Figlin (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.The New England journal of medicine, 356 2
(2010)
For personal use only. No other uses without permission All rights reserved
Díaz, Mora, Hakam (1999)
The Mainz Classification of Renal Cell Tumors.Cancer control : journal of the Moffitt Cancer Center, 6 6
C. Coppin, L. Lê, T. Wilt, C. Kollmannsberger (2008)
Targeted therapy for advanced renal cell carcinoma.The Cochrane database of systematic reviews, 2
F. Duffaud, P. Therasse (2000)
[New guidelines to evaluate the response to treatment in solid tumors].Bulletin du cancer, 87 12
E. Nelson, C. Evans, P. Lara (2007)
Renal cell carcinoma: current status and emerging therapies.Cancer treatment reviews, 33 3
(2010)
Information downloaded from jco.ascopubs.org and provided by at Seoul National Univ Med Libr on May 16, 2012 from Copyright
B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J. Bay, I. Bodrogi, A. Jagiełło-Gruszfeld, N. Moore (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 370
F. Bray, J. Ferlay, M. Laversanne, David Brewster, C. Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, Rajaraman Swaminathan, S. Antoni, Isabelle Soerjomataram, David Forman (1997)
Cancer Incidence in Five Continents
Mazen Karaman, S. Herrgård, D. Treiber, P. Gallant, Corey Atteridge, Brian Campbell, Katrina Chan, P. Ciceri, Mindy Davis, Philip Edeen, Raffaella Faraoni, Mark Floyd, Jeremy Hunt, Daniel Lockhart, Zdravko Milanov, M. Morrison, Gabriel Pallares, H. Patel, S. Pritchard, L. Wodicka, P. Zarrinkar (2008)
A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 26
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, F. Group (2008)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 372
R. Rabin, F. Charro (2001)
EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 33
N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N. Duez, A. Filiberti, H. Flechtner, S. Fleishman, J. Haes, S. Kaasa, M. Klee, D. Osoba, D. Razavi, Peter Rofe, S. Schraub, K. Sneeuw, M. Sullivan, F. Takeda (1993)
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.Journal of the National Cancer Institute, 85 5
H. Hurwitz, L. Fehrenbacher, J. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. Novotny, F. Kabbinavar (2005)
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
(2008)
Nat Biotechnol
R. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, J. Ferrara (1999)
Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 8
S. Négrier, D. Pérol, A. Ravaud, C. Chevreau, J. Bay, R. Delva, E. Sevin, A. Caty, B. Escudier (2007)
Medroxyprogesterone, interferon alfa‐2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosisCancer, 110
Journal of Clinical Oncology – Unpaywall
Published: Feb 20, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.